Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insmed, Tercica Head To Court Over Growth Hormone Patents

This article was originally published in The Pink Sheet Daily

Executive Summary

A San Francisco federal court denied four of Insmed’s five motions for summary judgment, sending the dispute over iPlex and Increlex to trial in November.

You may also be interested in...



Tercica Will Transition Patients On iPlex To Increlex Following Insmed Patent Settlement

Insmed will no longer provide iPlex growth hormone to short stature patients but can pursue development of the drug in certain other indications.

Tercica Will Transition Patients On iPlex To Increlex Following Insmed Patent Settlement

Insmed will no longer provide iPlex growth hormone to short stature patients but can pursue development of the drug in certain other indications.

Tercica Somatuline Autogel Launch Planned For 2007 Pending NDA Approval

Tercica’s partner, Ipsen, submitted an NDA for the acromegaly treatment Oct. 30.

Related Content

Topics

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel